» Articles » PMID: 9341897

Loss of Heterozygosity of the Nm23-H1 Gene in Human Renal Cell Carcinomas

Overview
Specialty Oncology
Date 1997 Jan 1
PMID 9341897
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

This study evaluates the potential contribution of the nm23-H1 gene to malignant transformation in patients with renal cell carcinoma. Using specific oligonucleotide primers for the nm23-H1 microsatellite repetitive sequence, gene instability was followed by polymerase chain reaction/loss of heterozygosity assay on 54 tumor specimens and the corresponding normal tissue samples. We also determined, immunohistochemically, the relative concentration and localization of the nm23-H1 protein product. From 77.7% informative cases, DNA from 6 tumors exhibited loss of heterozygosity, regardless of the tumor stage (TNM). Out of 39 samples analyzed, 30 were negative for Nm23-H1 protein, while the others were only slightly positive. No correlation with tumor stage was found. Normal renal tissue was also negative for this protein. Our results provide the evidence for loss of heterozygosity, followed by means of microsatellite tandem-repeat polymorphism, at the nm23-H1 locus in renal cell carcinoma. However, since no correlation was found between the tumor stage or metastatic potential on the one hand, and allelic loss and specific protein expression on the other, it seems that nm23-H1 does not play a key role in the invasiveness of this tumor type.

Citing Articles

Interaction between Nm23 and the tumor suppressor VHL.

Lin C, Dammai V, Adryan B, Hsu T Naunyn Schmiedebergs Arch Pharmacol. 2014; 388(2):143-52.

PMID: 24915993 DOI: 10.1007/s00210-014-1002-4.


nm23-H1 expression and loss of heterozygosity in colon adenocarcinoma.

Kapitanovic S, Cacev T, Berkovic M, Popovic-Hadzija M, Radosevic S, Seiwerth S J Clin Pathol. 2004; 57(12):1312-8.

PMID: 15563674 PMC: 1770523. DOI: 10.1136/jcp.2004.017954.


Increased nm23 immunoreactivity is associated with selective inhibition of systemic tumour cell dissemination.

Graham A, Maxwell P, Mulholland K, Patterson A, Anderson N, McManus K J Clin Pathol. 2002; 55(3):184-9.

PMID: 11896068 PMC: 1769616. DOI: 10.1136/jcp.55.3.184.


Nm23/nucleoside diphosphate kinase in human cancers.

Hartsough M, Steeg P J Bioenerg Biomembr. 2002; 32(3):301-8.

PMID: 11768314 DOI: 10.1023/a:1005597231776.

References
1.
Strohmeyer T, Slamon D . Proto-oncogenes and tumor suppressor genes in human urological malignancies. J Urol. 1994; 151(6):1479-97. DOI: 10.1016/s0022-5347(17)35284-9. View

2.
Jeffreys A, Wilson V, Thein S . Hypervariable 'minisatellite' regions in human DNA. Nature. 1985; 314(6006):67-73. DOI: 10.1038/314067a0. View

3.
Higashiyama M, Doi O, Yokouchi H, Kodama K, Nakamori S, Tateishi R . Immunohistochemical analysis of nm23 gene product/NDP kinase expression in pulmonary adenocarcinoma: lack of prognostic value. Br J Cancer. 1992; 66(3):533-6. PMC: 1977950. DOI: 10.1038/bjc.1992.308. View

4.
Florenes V, Aamdal S, Myklebost O, Maelandsmo G, Bruland O, Fodstad O . Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res. 1992; 52(21):6088-91. View

5.
Pavelic J, Galltroselj K, Hlavka V, Pavelic Z, Gluckman J, Stambrook P . Nm23-h1 protein in oligodendrogliomas. Int J Oncol. 2011; 4(6):1399-403. DOI: 10.3892/ijo.4.6.1399. View